FDA considers adding a dozen peptides to its bulk drug compounding list RAPS BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions